NEOL:

NEOPHARM Announces Fiscal 2006 Conference Call and Update on CINTREDEKIN BESUDOTOX
Thursday March 1, 4:05 pm ET


WAUKEGAN, Ill.--(BUSINESS WIRE)--NEOPHARM, Inc. (Nasdaq:NEOL - News) today announced that Guillermo Herrera, President and Chief Executive Officer, and other members of senior management, will hold a conference call and webcast to discuss fourth-quarter and full-year 2006 operating results and provide an update on CINTREKIN BESUDOTOX.
Wednesday, March 14, 2007 @ 11:00 a.m. Eastern/8:00 a.m. Pacific

Domestic: 866-831-6224, passcode 49061177
International: 617-213-8853, passcode 49061177

Simultaneous webcast and replays: www.neopharm.com

Audio replays will be available through March 21, 2007.

Domestic: 888-286-8010, passcode 52926685
International: 617-801-6888, passcode 52926685

NEOPHARM's Commitment to Oncology

NEOPHARM employees share a common goal: bringing hope to cancer patients and their families through the research and development of new cancer drugs and therapies. The Company's oncology portfolio is built on two novel, proprietary platforms: a tumor-targeting platform, and the NeoLipid® Liposomal Drug Delivery platform. Through its research and clinical studies, as well as its work with physicians, scientists, and advocacy groups, NEOPHARM is helping to enhance the lives of cancer patients.